In a report released yesterday, Irina Rivkind Koffler from Mizuho Securities maintained a Hold rating on Eagle Pharmaceuticals Inc (EGRX), with a price target of $50. The company’s shares closed yesterday at $52.04.
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 6.6% and a 39.8% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
Eagle Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $55, which is a 5.7% upside from current levels. In a report issued on April 15, Cantor Fitzgerald also maintained a Hold rating on the stock with a $58 price target.
See today’s analyst top recommended stocks >>
Based on Eagle Pharmaceuticals Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $12.59 million. In comparison, last year the company had a net profit of $2.62 million.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EGRX in relation to earlier this year. Last month, Steven Ratoff, a Director at EGRX bought 2,340 shares for a total of $9,454.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
